Role of fractalkine in monocytes in patients with rheumatoid arthritis

Research Project

Project/Area Number	17K09987
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Collagenous pathology/Allergology
Research Institution	Toho University
Principal Investigator	NANKI TOSHIHIRO 東邦大学, 医学部, 教授 (00282749)
Co-Investigator(Kenkyū-buntansha)	楠夏子東邦大学, 医学部, 博士研究員 (10328924)
Project Period (FY)	2017-04-01 – 2020-03-31
Project Status	Completed (Fiscal Year 2019)
Budget Amount *help	¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000) Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	関節リウマチ / フラクタルカイン / 単球 / 破骨細胞 / 樹状細胞
Outline of Final Research Achievements	The roles of fractalkine (FKN) on rheumatoid arthritis was analyzed. FKN did not alter production of inflammatory cytokines by peripheral blood monocytes. FKN upregulated osteoclast differentiation from peripheral blood CD16- monocytes. Furthermore, FKN upregulated osteoclast formation from dendritic cells derived from peripheral blood CD16- monocytes. These results suggest that FKN might have roles of not only inflammatory cell accumulation, but also bone destruction, on rheumatoid arthritis.
Academic Significance and Societal Importance of the Research Achievements	現在、抗フラクタルカイン（FKN）抗体による関節リウマチに対する治験が行われている。本研究結果は関節リウマチにおけるFKNの作用の一つを明らかにしたものであり、今後、抗FKN抗体が関節リウマチに使用できるようになった際には、その期待できる治療効果を予測したり、また適応患者の選択にも役立つ。